Key result
Doxorubicin chemotherapy significantly increased median cTnT levels from 4.90 to 14.00 ng/mL and GDF-15 levels from 689.70 to 1259.40 pg/mL by the end of treatment.
Why the study?
Biomarkers represent a potential tool to identify patients at risk for anthracycline-induced cardiotoxicity prior to symptom onset or left ventricular dysfunction.
Does doxorubicin-containing chemotherapy alter cardiac and noncardiac biomarker levels in adult patients with malignancies?
Cohort (n=41)
No
Does doxorubicin-containing chemotherapy alter cardiac and noncardiac biomarker levels in adult patients with malignancies?
Absolute Event Rate: 14% vs 4.9%
p-value: p=<0.001
Cardiac biomarkers cTnT and GDF-15 significantly increase following anthracycline chemotherapy, highlighting their potential utility for early detection of cardiotoxicity.
Anthracycline-associated biomarker rises may aid cardiotoxicity monitoring; hypothesis-generating and should not change practice without prospective trials.
Background Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. Methods This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m 2 ) and low exposure groups. Results The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. Conclusions The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers.
No takes yet. Share an insight, caveat, or question.
Dean et al. (2023) conducted a cohort in Hematologic or solid tumor malignancies (n=41). Doxorubicin chemotherapy vs. Baseline (Pre-chemotherapy) was evaluated on Change in median high-sensitivity cardiac troponin T (cTnT) levels (ng/mL) from pre-chemotherapy to end-chemotherapy (p=<0.001). Doxorubicin chemotherapy significantly increased median cTnT levels from 4.90 to 14.00 ng/mL and GDF-15 levels from 689.70 to 1259.40 pg/mL by the end of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: